New Clinical Trial – BCX4161-301 (OPuS-2)

  • haeadm 

We are excited to tell you about some new clinical trials that will be happening in Canada. Biocryst will be overseeing several studies across the country. There is more information below. 

If you have any questions about this or anything else please don’t hesitate to contact us.

BCX4161-301 (OPuS-2) 

An oral investigational drug is being evaluated in adults with Hereditary Angioedema (HAE). The purpose of the research study is to assess whether taking the study drug prevents and/or reduces the frequency of attacks compared to placebo. Each patient will participate in a 12-week dosing period and will be asked to come to the research clinic 6 times over a 4- 6 month period. Patients will record their HAE attacks and study drug dosing in an electronic diary daily. Patients should have access to and take their on-demand treatment for acute attacks at any time as needed during the study. Additional information about the study can be found at:

Canada Specific Information


Download (PDF, Unknown)

Leave a Reply

Your email address will not be published. Required fields are marked *